Detalles de la búsqueda
1.
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Ann Oncol
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38777726
2.
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
Ann Oncol
; 34(11): 1025-1034, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37619846
3.
Inflammation biomarkers and inflammatory genes expression in metabolically healthy obese patients.
Nutr Metab Cardiovasc Dis
; 33(3): 584-591, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36642614
4.
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
Ann Oncol
; 33(10): 1052-1060, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764271
5.
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Ann Oncol
; 32(5): 600-608, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539945
6.
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.
Ann Oncol
; 32(1): 66-76, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098997
7.
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Ann Oncol
; 31(4): 480-486, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32085892
8.
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Ann Oncol
; 30(9): 1466-1471, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31268130
9.
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Ann Oncol
; 30(12): 1969-1977, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31573612
10.
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Ann Oncol
; 30(1): 124-131, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30339194
11.
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
Ann Oncol
; 29(9): 1955-1963, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30010751
12.
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
Ann Oncol
; 29(7): 1528-1534, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29873679
13.
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Ann Oncol
; 29(4): 924-930, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29324972
14.
Cutaneous infiltration of plasmacytoid dendritic cells and T regulatory cells in skin lesions of polymorphic light eruption.
J Eur Acad Dermatol Venereol
; 32(6): 985-991, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29430717
15.
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Br J Cancer
; 117(9): 1269-1277, 2017 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29065426
16.
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
Ann Oncol
; 28(3): 555-561, 2017 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27864220
17.
Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study.
Tech Coloproctol
; 21(8): 633-640, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28755256
18.
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Ann Oncol
; 27(5): 843-9, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26861604
19.
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Ann Oncol
; 27(11): 2082-2090, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27573561
20.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Ann Oncol
; 27(11): 2074-2081, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27573560